Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells - PubMed (original) (raw)
Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells
H W Stürzbecher et al. Mol Cell Biol. 1988 Sep.
Abstract
Several mutant, but not wild-type, p53 proteins form complexes with hsp72/73 heat shock-related proteins in simian virus 40-transformed monkey COS cells. We carried out a detailed biochemical and structural mapping analysis of p53 and report here that p53-hsp72/73 complex formation showed considerable structural specificity. Such complexes were remarkably stable, but unlike analogous complexes formed between p53 and simian virus 40 T antigen, they did not form in in vitro association assays. p53-hsp72/73 complex formation in vivo appears to be dependent on aspects of mutant p53 protein conformation. However, absence of the conformation-sensitive epitope recognized by monoclonal antibody PAb 246 was not reliably diagnostic of such complexes, nor was p53-hsp72173 binding reliably diagnostic of oncogenic activation.
Similar articles
- Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells.
Stürzbecher HW, Chumakov P, Welch WJ, Jenkins JR. Stürzbecher HW, et al. Oncogene. 1987 May;1(2):201-11. Oncogene. 1987. PMID: 2830579 - Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex.
Tan TH, Wallis J, Levine AJ. Tan TH, et al. J Virol. 1986 Sep;59(3):574-83. doi: 10.1128/JVI.59.3.574-583.1986. J Virol. 1986. PMID: 3016321 Free PMC article. - Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.
Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Finlay CA, et al. Mol Cell Biol. 1988 Feb;8(2):531-9. doi: 10.1128/mcb.8.2.531-539.1988. Mol Cell Biol. 1988. PMID: 2832726 Free PMC article. - Major heat shock protein Hsp72 controls oncogene-induced senescence.
Sherman M. Sherman M. Ann N Y Acad Sci. 2010 Jun;1197:152-7. doi: 10.1111/j.1749-6632.2010.05196.x. Ann N Y Acad Sci. 2010. PMID: 20536844 Review. - The p53 tumor suppressor gene and gene product.
Levine AJ. Levine AJ. Princess Takamatsu Symp. 1989;20:221-30. Princess Takamatsu Symp. 1989. PMID: 2488233 Review.
Cited by
- Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
Schulz-Heddergott R, Moll UM. Schulz-Heddergott R, et al. Cancers (Basel). 2018 Jun 7;10(6):188. doi: 10.3390/cancers10060188. Cancers (Basel). 2018. PMID: 29875343 Free PMC article. Review. - Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies.
Würl P, Taubert H, Meye A, Berger D, Lautenschläger C, Holzhausen HJ, Schmidt H, Kalthoff H, Rath FW, Dralle H. Würl P, et al. J Cancer Res Clin Oncol. 1997;123(9):502-8. doi: 10.1007/BF01192205. J Cancer Res Clin Oncol. 1997. PMID: 9341900 - Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Blagosklonny MV, et al. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8379-83. doi: 10.1073/pnas.93.16.8379. Proc Natl Acad Sci U S A. 1996. PMID: 8710879 Free PMC article. - Conformational effects of environmentally induced, cancer-related mutations in the p53 protein.
Brandt-Rauf PW, Monaco R, Pincus MR. Brandt-Rauf PW, et al. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9262-6. doi: 10.1073/pnas.91.20.9262. Proc Natl Acad Sci U S A. 1994. PMID: 7937752 Free PMC article.
References
- EMBO J. 1985 Mar;4(3):699-706 - PubMed
- Nature. 1984 Dec 13-19;312(5995):651-4 - PubMed
- EMBO J. 1985 Dec 16;4(13A):3385-91 - PubMed
- Nature. 1986 Mar 13-19;320(6058):182-4 - PubMed
- Cell. 1986 Apr 11;45(1):3-13 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous